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Abstract
Deleterious BRCA2 genetic variants markedly increase risk of developing breast cancer. A rare truncating BRCA2 genetic 
variant, rs11571833 (K3326X), has been associated with a 2.5-fold risk of lung squamous cell carcinoma but only a modest 
26% increase in breast cancer risk. We analyzed the association between BRCA2 SNP rs11571833 and upper aerodigestive 
tract (UADT) cancer risk with multivariable unconditional logistic regression adjusted by sex and combinations of study 
and country for 5942 UADT squamous cell carcinoma case patients and 8086 control patients from nine different studies. 
All statistical tests were two-sided. rs11571833 was associated with UADT cancers (odds ratio = 2.53, 95% confidence 
interval = 1.89 to 3.38, P = 3x10-10) and was present in European, Latin American, and Indian populations but extremely 
rare in Japanese populations. The association appeared more apparent in smokers (current or former) compared with 
never smokers (Phet = .026). A robust association between a truncating BRCA2 variant and UADT cancer risk suggests that 
treatment strategies orientated towards BRCA2 mutations may warrant further investigation in UADT tumors.
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Upper aerodigestive tract (UADT) cancers, predominantly 
squamous cell in origin, comprise the oral cavity, larynx, 
and esophagus. UADT cancers are the fourth most common 
cause of cancer death worldwide (1). Consumption of tobacco 
and alcohol are established UADT cancer risk factors (2), but 
genetic epidemiology (3) and familial studies (4) provide evi-
dence for a role of genetic susceptibility in the pathogenesis 
of this disease.
Exposure to tobacco and alcohol leads to cell damage and 
DNA alterations that, in the absence of repair, may cause cell 
cycle deregulation and cancer development (5,6). DNA repair 
genes, like BRCA2, play an important role in repair of DNA lesions 
(7,8), and germline genetic variation affecting gene function may 
modulate disease risk. A recent imputation-based genome-wide 
association study of 21 597 lung cancer case patients and 54 083 
control patients identified a rare truncating BRCA2 genetic vari-
ant, rs11571833 (K3326X), to be robustly associated with lung 
cancer. While present in lung adenocarcinomas (odds ratio 
[OR]  =  1.47, P  =  5x10-4), the association was more pronounced 
in lung squamous cell carcinomas (OR = 2.47, P = 10–20) (9). As 
squamous cell carcinomas (SCCs) of different anatomical sites 
share many phenotypic and molecular characteristics (10), the 
present study investigated rs11571833 in the context of genetic 
susceptibility to UADT cancers.
We explored rs11571833 in nine UADT cancer case-control 
studies (study designs and population characteristics have 
been described previously [3,11,12]) totalling 5942 UADT can-
cer case patients and 8086 control patients (Table 1). Study par-
ticipants underwent informed consent and approval by local 
and International Agency for Research on Cancer institutional 
ethics (IRB) review. rs11571833 was genotyped using Taqman 
(C__27537307_30 Applied Biosystems, Carlsbad, CA), with 
operators blinded to case-control status, as described else-
where (9). Regenotyping samples of known genotype obtained 
Table 1. Demographic characteristics of the case patients and control patients included in the genetic susceptibility study of BRCA2 rs11571833 
genetic variant*
Case patients Control patients MAF control patients MAF case patients
Study name/population  
characteristics Study setting
ARCAGE Europe - multicenter 1401 1505 0.006 0.017
Central-Europe Europe - multicenter 741 1652 0.005 0.015
Rome (HNI) Roma - Italy 309 231 0.009 0.024
ACTREC India 220 358 0.010 0.002
Japan Aichi Cancer Center Hospital 556 1203 0.000 0.001
SA Latin America - multicenter 1493 1207 0.006 0.011
Oral cancer (ORC) Europe - multicenter 419 457 0.005 0.013
Oral cancer (ORC) India 401 457 0.004 0.012
Poland Szczecin - Poland 402 1016 0.003 0.011
Sex
Male 4584 5966 0.004 0.012
Female 1358 2120 0.005 0.013
Age group
<50 y 1091 1629 0.005 0.013
≥50 y 4447 6456 0.004 0.013
Missing 404 1 0.000 0.011
Smoking status
Never smokers 847 2632 0.006 0.005
Ever smokers 4686 4433 0.005 0.014
Former 1145 1981 0.003 0.013
Current 3485 2338 0.005 0.014
Missing 56 114 0.009 0.000
Missing 409 1021 0.003 0.013
Alcohol intake status
Never drinkers 915 1927 0.004 0.010
Ever drinkers 4614 5141 0.005 0.013
Former 720 508 0.007 0.017
Current 2575 2514 0.004 0.011
Missing 1319 2119 0.006 0.014
Missing 413 1018 0.003 0.013
Site of tumor
Oral cavity 2230 0.011
Oropharynx 856 0.013
Larynx/hypopharynx 2195 0.014
Esophagus 635 0.012
Missing 26 0.019
* ACTREC = Advanced Centre for Treatment, Research and Education in Cancer oral cancer study; ARCAGE = Alcohol Related CAncers and Genetic susceptibility in 
Europe; HNI = Rome (Italy) head and neck cancer study; MAF = minor allele frequency; ORC= IARC multicentre oral cancer case control study; SA = South America.
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by orthogonal genotyping techniques (90 Hapmap CEU sam-
ples where one individual was heterozygous) and direct DNA 
sequencing of Taqman-defined heterozygote individuals 
(n = 10) confirmed the fidelity of the Taqman assay. Internal 
study duplicate (approximately 8% from each study) concord-
ance was over 99%. rs11571833 minor allele (T) was rare in 
Europe and Latin America, with a minor allele frequency in 
control patients of 0.50% and 0.62%, respectively, less promi-
nent in the Indian subcontinent (0.27%) and extremely rare 
in Japan (only one single heterozygote observed in case 
patients and none in the 1203 control individuals). rs11571833 
homozygote individuals were not observed, although none 
were expected given the variant frequency and genotype 
distributions expected under Hardy-Weinberg equilibrium. 
We used multivariable unconditional logistic regression with 
variables for sex and combinations of study and country 
included in the model as covariables. All statistical tests were 
two-sided. rs11571833 was strongly associated with UADT 
cancers (OR = 2.53, 95% CI = 1.89 to 3.38, two sided P = 3x10-10), 
with the minor allele carriers of BRCA2 rs11571833 having an 
important 2.5-fold increased risk of UADT cancers (Figure 1). 
Within the Central-European and alcohol-related cancers 
and genetic susceptibility in European head and neck cancer 
studies where genome-wide genotyping data were available, 
this association did not appear sensitive to cryptic population 
structure, as adjusting for genotype inferred genetic ances-
try had little effect (Supplementary Table 1, available online). 
rs11571833 has been previously associated with increased 
risk of squamous cell esophageal cancers (13,14), a finding 
we replicated in an independent study population (OR = 3.30, 
P = 3x10-4) and extended to other UADT cancer subsites (Phet 
=. 58) (Figure 1). Serological HPV16E6 status has been defined 
for 514/856 of the oro-pharyngeal cancers presented here 
(15,16); however, only two oro-pharyngeal cancers and one 
control patient were both HPVE6-positive and rs11571833 car-
riers. The association appeared consistent across the various 
studies (Phet = .33) and by drinking status (Phet = .63), although 
it appeared to vary somewhat by smoking status (Phet = .026), 
with little evidence for association within never smok-
ers. Where survival information was available (the ARCAGE 
study), there was a tendency for decreased overall survival in 
allele carriers compared with noncarriers (hazard ratio = 1.72, 
P = .05), although this result should be interpreted with cau-
tion as it is based on low numbers (Supplementary Figure 1, 
available online).
While less common than cancers of the prostate, pancreas, 
and ovary, some excess of laryngeal and pharyngeal cancers 
have also been reported in BRCA2 mutation–positive families 
(17,18), implying a potential role for deleterious BRCA2 muta-
tions in UADT cancer genetic susceptibility. Germline mutations 
Figure 1. Association between BRCA2 SNP rs11571833 and upper aerodigestive tract cancer risk. Squares represent odds ratios, size of the square represents the inverse 
of the variance of the log odds ratios; horizontal lines represent 95% confidence intervals. The solid vertical line indicates an odds ratio of 1 and the dashed vertical line 
the overall odds ratio. The arrow indicates that the confidence interval of this particular estimate exceeds the scale of the plot. Results derived from a two-sided mul-
tivariable unconditional logistic regression adjusted by sex and study-specific country. All statistical tests were two-sided. ACTREC = Advanced Centre for Treatment, 
Research and Education in Cancer oral cancer study; CI = confidence interval; HNI = Rome (Italy) head and neck cancer study; OR = odds ratio; ORC = IARC multicentre 
oral cancer case control study; SA = South America.
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in the BRCA2 gene have also been implicated in Fanconi Anemia 
(19), which includes UADT cancers within its disease spectrum 
(20,21). We did not identify any additional deleterious germline 
BRCA2 mutations in our genetic analysis of the germline exome 
sequences of 10 head and neck squamous cell (HNSC) carcino-
mas in carriers of rs11571833 identified by The Cancer Genome 
Atlas (TCGA) initiative. Although numbers are small, these 
observations, together with similar ones made in 24 rs11571833 
lung cancer carriers (9), suggest that linkage disequilibrium (LD) 
with additional BRCA2 mutations appears unlikely to explain the 
association. rs11571833 encodes a truncated form of the BRCA2 
protein, resulting in the loss of the final 93 amino acids and is 
not considered a high-risk breast cancer allele (22). Consistent 
with this, in vitro studies suggest that K3326X does not have 
comparable functional consequences to the gene product as do 
the deleterious BRCA2 breast cancer susceptibility alleles (23). 
Somatic loss (somatic mutation or loss of heterozygosity) of the 
wild-type allele of the BRCA2 gene was not observed in the 10 
TCGA HNSC rs11571833 carriers: This is similar to lung cancer 
(9), whereas this loss is common in BRCA2 germline mutation–
positive breast tumors.
The limitations of this study are the rarity of rs11571833, 
which constrains our statistical power to investigate the hetero-
geneity of the association across substrata or correlations with 
factors such as tumor loss of heterozygosity. Nor was it possi-
ble to rule out that rs11571833 is an LD proxy for a variant in 
another gene, although rs11571833 is itself a noteworthy variant 
in a relevant gene.
rs11571833 has been associated with pancreatic cancer 
(24) and a modest but statistically significantly increased risk 
(26%) of breast cancer (OR = 1.26) (25). The 2.5-fold increase in 
genetic risk noted for UADT cancer here and squamous cell 
lung cancers (9) is markedly higher. The difference in risk, 
together with the ambiguous functional consequence of this 
variant, suggests an alternate susceptibility mechanism for 
K3326X compared with the highly deleterious BRCA2 breast 
cancer susceptibility alleles. Nevertheless, although the pop-
ulation-attributable fraction remains modest (0.7%), a robust 
association between a truncating BRCA2 variant and UADT 
cancer risk suggests that treatment strategies like PARP1 
inhibitors or synthetic lethality approaches targeting RAD52 
and BRCA2 (26,27) may warrant further consideration in UADT 
tumors.
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